JETO HomeIssue Contents

Proceeding Editorial
Targeting inflammatory cell signaling mechanisms:
A promising road to new therapeutic agents in chemoprevention and cancer therapy
Michael Schnekenburger, Tommy Karius, Claudia Cerella and Marc Diederich

The more studies are advancing allowing comprehension of inflammatory mechanisms, the more we become aware of the elaborate nature of this biological process. The current knowledge, indeed, is depicting a complex scenario, where inflammatory mediators and modulators appear implicated in the control and maintenance of a number of essential homeostatic functions. The accumulating findings are suggestive of non-canonical jobs carried on by the inflammatory cell signaling pathways that prompt us to constantly update our notion. Besides, it has become evident that the deregulation of this complex interplay is responsible for the insurgence of pathological degenerations, including autoimmune diseases and cancer. Targeting these aberrations may thus represent a rich soil for the development of future therapeutics.

The meeting “Inflammation 2010-Inflammatory cell signaling mechanisms as therapeutic targets” held last January (27th–30th) in Luxembourg, gathered more than 550 participants at the brand new European Congress center from Luxembourg city located in the Kirchberg neighborhood. This well-organized meeting covered the all world of inflammation from basic research to therapeutic applications and it was a great opportunity for the scientific community to share their work and to report recent findings and ongoing research in cell signaling, inflammation, innate immunity, inflammation related diseases and cancer…

Full Text (IP)